Abvc Biopharma (ABVC) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Abvc Biopharma (ABVC) over the last 5 years, with Q3 2025 value amounting to -$0.05.
- Abvc Biopharma's EPS (Weighted Average and Diluted) fell 6666.67% to -$0.05 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 14166.67%. This contributed to the annual value of -$0.42 for FY2024, which is 7666.67% up from last year.
- Per Abvc Biopharma's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.05 for Q3 2025, which was down 6666.67% from -$0.13 recorded in Q2 2025.
- In the past 5 years, Abvc Biopharma's EPS (Weighted Average and Diluted) ranged from a high of $0.28 in Q4 2023 and a low of -$1.54 during Q4 2022
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.33, with a median of -$0.11 in 2021.
- As far as peak fluctuations go, Abvc Biopharma's EPS (Weighted Average and Diluted) crashed by 159224.15% in 2022, and later soared by 11822.82% in 2023.
- Over the past 5 years, Abvc Biopharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.32 in 2021, then crashed by 385.16% to -$1.54 in 2022, then soared by 118.23% to $0.28 in 2023, then crashed by 117.86% to -$0.05 in 2024, then dropped by 0.0% to -$0.05 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.05 in Q3 2025, compared to -$0.13 in Q2 2025 and -$0.06 in Q1 2025.